Has Charles Manner received payments from drug or device companies?

Yes. Drug and device makers reported $13,100 in general payments to Charles Manner across 754 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Charles Manner did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Charles Manner come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Charles Manner

Hematology & Oncology · Houston, TXNPI 1760443782

Payments from drug & device makers

$13,100in general payments, 2019–2025

Across 754 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$1K
Johnson & Johnson$1K
AstraZeneca$838
Merck$738
Amgen$718
Bristol Myers Squibb$665
plus $8K from 54 others

What the payments were for

Food & beverage$12,71097%
Education$3903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	71	$1,139
Johnson & Johnson(2 entities)	63	$1,045
AstraZeneca(2 entities)	47	$838
Merck	40	$738
Amgen	35	$718
Bristol Myers Squibb	50	$665
E.r. Squibb & Sons, L.L.C.	42	$626
Sanofi	31	$583
Pfizer	38	$513
GSK	22	$509
Pharmacyclics LLC, An Abbvie Company	18	$388
Takeda Pharmaceuticals U.S.A., Inc.	21	$364
Eisai Inc.	18	$338
Beigene USA, Inc.	17	$307
Seagen Inc.	15	$276
Daiichi Sankyo Inc.	10	$211
Boehringer Ingelheim	14	$199
Bayer	12	$194
Lilly USA, LLC	12	$184
Taiho Oncology, Inc.	11	$182
Genentech USA, Inc.	10	$170
Myriad Genetic Laboratories, Inc.	2	$156
Exelixis Inc.	10	$154
Verity Pharmaceuticals Inc.	6	$129
Gilead(2 entities)	7	$127
Incyte Corporation	8	$126
Rigel Pharmaceuticals, Inc.	9	$125
EMD Serono, Inc.	7	$116
Boston Scientific	2	$104
Tesaro, Inc.	5	$100
Regeneron Healthcare Solutions, Inc.	5	$100
AbbVie	5	$98
Servier Pharmaceuticals LLC	5	$97
Astellas Pharma US Inc	6	$92
Agios Pharmaceuticals, Inc.	6	$86
Puma Biotechnology, Inc.	4	$80
Tersera Therapeutics LLC	3	$79
Kyowa Kirin, Inc.	4	$76
Acrotech Biopharma Inc.	4	$70
AVEO Pharmaceuticals, Inc.	3	$68
Morphosys, US Inc.	4	$67
Mylan Institutional Inc.	5	$67
Dova Pharmaceuticals	4	$60
Adaptive Biotechnologies Corporation	3	$60
Teva Pharmaceuticals USA, Inc.	3	$55
Tempus AI, Inc	3	$52
Springworks Therapeutics, Inc.	3	$49
Array Biopharma Inc	3	$49
Pharmaessentia USA Corporation	2	$41
Aurobindo Pharma USA, Inc.	2	$38
Jazz Pharmaceuticals Inc.	2	$36
Acceleron Pharma, Inc.	2	$33
Ipsen Biopharmaceuticals, Inc	2	$30
Blue Earth Diagnostics	2	$29
Blueprint Medicines Corporation	2	$26
Lexicon Pharmaceuticals, Inc.	2	$25
Secura Bio, Inc.	2	$24
CTI Biopharma Corp.	1	$24
G1 Therapeutics, Inc.	1	$23
Macrogenics, Inc.	1	$23

How this compares

$13,100 in reported general payments places this provider in the 50th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas →

Other hematology & oncology in Houston

Elias JabbourHouston$264.1M
Luhua WangHouston$79.6M
Courtney DinardoHouston$74M
Jorge Cortes-FrancoHouston$59.4M
William WierdaHouston$58.7M
Koji SasakiHouston$39.2M
Loretta NastoupilHouston$18.3M
Christopher FlowersHouston$17.2M
Philip ThompsonHouston$13.6M
Naval DaverHouston$13.6M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →